Wendy R. Parulekar

30.5k total citations · 6 hit papers
131 papers, 14.9k citations indexed

About

Wendy R. Parulekar is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Wendy R. Parulekar has authored 131 papers receiving a total of 14.9k indexed citations (citations by other indexed papers that have themselves been cited), including 61 papers in Pulmonary and Respiratory Medicine, 57 papers in Oncology and 36 papers in Cancer Research. Recurrent topics in Wendy R. Parulekar's work include Prostate Cancer Treatment and Research (28 papers), Prostate Cancer Diagnosis and Treatment (22 papers) and Breast Cancer Treatment Studies (20 papers). Wendy R. Parulekar is often cited by papers focused on Prostate Cancer Treatment and Research (28 papers), Prostate Cancer Diagnosis and Treatment (22 papers) and Breast Cancer Treatment Studies (20 papers). Wendy R. Parulekar collaborates with scholars based in Canada, United States and United Kingdom. Wendy R. Parulekar's co-authors include Jesse A. Berlin, David Moher, Douglas G. Altman, Kenneth F. Schulz, Peter C Gøtzsche, Kay Dickersin, Jennifer Tetzlaff, Karmela Krleža-Jerić, A. Laupacis and H Mann and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Wendy R. Parulekar

123 papers receiving 14.7k citations

Hit Papers

SPIRIT 2013 Statement: Defining Standard Protocol Items f... 2007 2026 2013 2019 2013 2013 2007 2008 2016 1000 2.0k 3.0k 4.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials
    2013 4.4k citations Jennifer Tetzlaff, Douglas G. Altman et al. profile →
  2. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials
    2013 3.6k citations Jennifer Tetzlaff, Peter C Gøtzsche et al. profile →
  3. Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
    2007 2.9k citations Malcolm J. Moore, Keyue Ding et al. Journal of Clinical Oncology profile →
  4. Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials
    2008 534 citations J. W. Chapman, Wendy R. Parulekar et al. Journal of Clinical Oncology profile →
  5. Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years
    2016 411 citations Paul E. Goss, James N. Ingle et al. New England Journal of Medicine profile →
  6. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial
    2011 382 citations Keyue Ding, Mahesh Parmar et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Wendy R. Parulekar Canada 30 5.2k 3.1k 2.3k 1.9k 1.6k 131 14.9k
William E. Barlow United States 76 7.6k 1.5× 3.4k 1.1× 1.2k 0.5× 3.5k 1.8× 1.5k 0.9× 277 19.9k
Timothy L. Lash United States 60 3.6k 0.7× 1.4k 0.5× 1.3k 0.6× 1.9k 1.0× 1.1k 0.7× 348 15.0k
Chris R. Cardwell United Kingdom 57 2.1k 0.4× 2.8k 0.9× 2.3k 1.0× 1.0k 0.5× 1.5k 1.0× 307 12.7k
Yong‐Fang Kuo United States 61 3.2k 0.6× 3.3k 1.0× 2.2k 0.9× 981 0.5× 593 0.4× 497 14.0k
Joseph L. Pater Canada 51 8.1k 1.6× 6.2k 2.0× 3.1k 1.3× 2.0k 1.0× 1.4k 0.9× 147 16.3k
Gunnar Steineck Sweden 66 3.9k 0.8× 5.6k 1.8× 4.5k 1.9× 1.5k 0.8× 1.7k 1.1× 395 17.3k
Alexandra L. Hanlon United States 64 2.9k 0.6× 6.2k 2.0× 2.8k 1.2× 1.8k 1.0× 1.0k 0.7× 384 14.3k
André L. M. Verbeek Netherlands 57 3.8k 0.7× 2.2k 0.7× 2.3k 1.0× 1.5k 0.8× 826 0.5× 293 11.8k
Amylou C. Dueck United States 52 5.0k 1.0× 1.6k 0.5× 1.1k 0.5× 1.2k 0.6× 1.5k 1.0× 353 11.0k
James S. Goodwin United States 83 6.9k 1.3× 4.0k 1.3× 2.5k 1.1× 2.2k 1.1× 1.3k 0.8× 442 24.7k

Countries citing papers authored by Wendy R. Parulekar

Since Specialization
Citations

This map shows the geographic impact of Wendy R. Parulekar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wendy R. Parulekar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wendy R. Parulekar more than expected).

Fields of papers citing papers by Wendy R. Parulekar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wendy R. Parulekar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wendy R. Parulekar. The network helps show where Wendy R. Parulekar may publish in the future.

Co-authorship network of co-authors of Wendy R. Parulekar

This figure shows the co-authorship network connecting the top 25 collaborators of Wendy R. Parulekar. A scholar is included among the top collaborators of Wendy R. Parulekar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wendy R. Parulekar. Wendy R. Parulekar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ravi, Praful, Wanling Xie, Marc Buyse, et al.. (2024). Refining Risk Stratification of High-risk and Locoregional Prostate Cancer: A Pooled Analysis of Randomized Trials. European Urology. 87(2). 217–224. 2 indexed citations
2.
Karam, Irene, Eric Berthelet, Andrea McNiven, et al.. (2024). A Phase II Single Arm Trial of Elective Volume Adjusted De-Escalation Radiotherapy (EVADER) in Patients with Low-risk HPV-related Oropharyngeal Squamous Cell Carcinoma. International Journal of Radiation Oncology*Biology*Physics. 120(2). S7–S8. 3 indexed citations
3.
4.
Hershman, Dawn L., Bingshu E. Chen, Wendy R. Parulekar, et al.. (2023). Metformin, placebo, and endocrine therapy discontinuation among participants in a randomized double-blind trial of metformin vs placebo in hormone receptor-positive early-stage breast cancer (CCTG MA32). Breast Cancer Research and Treatment. 200(1). 93–102. 6 indexed citations
5.
Goodwin, Pamela J., Bingshu E. Chen, Karen A. Gelmon, et al.. (2023). Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA.32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast Cancer. Journal of Clinical Oncology. 41(35). 5356–5362. 11 indexed citations
6.
Clarke, Noel W., René Horsleben Petersen, Heather Payne, et al.. (2023). 1764O Timing of radiotherapy (RT) after radical prostatectomy (RP): Final results of RADICALS RT randomised controlled trial. Annals of Oncology. 34. S953–S953.
7.
Almeida, John R. de, Brian O’Sullivan, David P. Goldstein, et al.. (2021). Comparing unilateral vs. bilateral neck management in lateralized oropharyngeal cancer between surgical and radiation oncologists: An international practice pattern survey. Oral Oncology. 114. 105165–105165. 6 indexed citations
8.
Gu, Shengqing, Stéphanie Lheureux, Azin Sayad, et al.. (2021). Computational modeling of ovarian cancer dynamics suggests optimal strategies for therapy and screening. Proceedings of the National Academy of Sciences. 118(25). 12 indexed citations
9.
Ethier, Josée-Lyne, Geoffrey M. Anderson, Peter C. Austin, et al.. (2021). Influence of the competing risk of death on estimates of disease recurrence in trials of adjuvant endocrine therapy for early-stage breast cancer: A secondary analysis of MA.27, MA.17 and MA.17R. European Journal of Cancer. 149. 117–127. 7 indexed citations
10.
Goodwin, Pamela J., Ryan J.O. Dowling, Marguerite Ennis, et al.. (2021). Cancer Antigen 15-3/Mucin 1 Levels in CCTG MA.32: A Breast Cancer Randomized Trial of Metformin vs Placebo. JNCI Cancer Spectrum. 5(5). 12 indexed citations
11.
Gross, Jeffrey P., Timothy J. Whelan, Wendy R. Parulekar, et al.. (2019). Development and Validation of a Nomogram to Predict Lymphedema After Axillary Surgery and Radiation Therapy in Women With Breast Cancer From the NCIC CTG MA.20 Randomized Trial. International Journal of Radiation Oncology*Biology*Physics. 105(1). 165–173. 38 indexed citations
12.
Huang, Jessica, J. W. Chapman, Kim Leitzel, et al.. (2017). Impact of serum HER2, TIMP-1, and CAIX on outcome for HER2+ metastatic breast cancer patients: CCTG MA.31 (lapatinib vs. trastuzumab). Breast Cancer Research and Treatment. 164(3). 571–580. 11 indexed citations
13.
Yerushalmi, Rinat, Bin Dong, Judith‐Anne W. Chapman, et al.. (2017). Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials. Annals of Oncology. 28(7). 1560–1568. 21 indexed citations
14.
Goss, Paul E., James N. Ingle, Kathleen I. Pritchard, et al.. (2016). Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. New England Journal of Medicine. 375(3). 209–219. 411 indexed citations breakdown →
15.
Péron, Julien, Pascal Roy, Keyue Ding, et al.. (2015). Assessing the benefit–risk of new treatments using generalised pairwise comparisons: the case of erlotinib in pancreatic cancer. British Journal of Cancer. 112(6). 971–976. 22 indexed citations
16.
Tetzlaff, Jennifer, Douglas G. Altman, Andreas Laupacis, et al.. (2013). Spirit 2013 statement: Defining standard protocol items for clinical trials. Zhongguo xunzheng yixue zazhi. 13(12). 1501–1507. 4 indexed citations
17.
Santos, Gilda da Cunha, Neesha C. Dhani, Dongsheng Tu, et al.. (2010). Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer. Cancer. 116(24). 5599–5607. 117 indexed citations
18.
Chen, Chien‐Hung, Sandip Sengupta, Ralph George, et al.. (2009). Primary Basaloid Carcinoma of the Nipple with Associated Squamous Cell Carcinoma in Situ. The Breast Journal. 15(4). 409–413. 1 indexed citations
19.
Parulekar, Wendy R.. (2003). Dry Talc Pleurodesis Via Chest Tube. CHEST Journal. 123(1). 308–308. 2 indexed citations
20.
Parulekar, Wendy R., Gina Di Primio, Fred Matzinger, Carole Dennie, & Gregory Bociek. (2001). Use of Small-Bore vs Large-Bore Chest Tubes for Treatment of Malignant Pleural Effusions. CHEST Journal. 120(1). 19–25. 93 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by William E. Barlow Breakdown of academic impact, for papers by Timothy L. Lash Breakdown of academic impact, for papers by Chris R. Cardwell Breakdown of academic impact, for papers by Yong‐Fang Kuo Breakdown of academic impact, for papers by Joseph L. Pater Breakdown of academic impact, for papers by Gunnar Steineck Breakdown of academic impact, for papers by Alexandra L. Hanlon Breakdown of academic impact, for papers by André L. M. Verbeek Breakdown of academic impact, for papers by Amylou C. Dueck Breakdown of academic impact, for papers by James S. Goodwin
Rankless by CCL
2026